Aurobindo Pharma Reports 2% Increase in Q4 Profit After Tax
Aurobindo Pharma Q4 PAT edges up 2 pc at Rs 920.84 cr
Image: News 18
Aurobindo Pharma Ltd, based in New Delhi, reported a 2% increase in its consolidated profit after tax to ₹920.84 crore (approximately $111 million USD) for the fourth quarter ending March 31. The company's total revenue from operations also rose to ₹8,853.34 crore (around $1.07 billion USD), reflecting growth in its financial performance.
- 01The consolidated profit after tax for FY26 reached ₹3,502.97 crore (approximately $426 million USD), up from ₹3,483.57 crore in FY25.
- 02Total revenue from operations for FY26 was ₹33,653.08 crore (around $4.05 billion USD), compared to ₹31,723.73 crore in FY25.
- 03Total expenses for Q4 FY26 increased to ₹7,677.34 crore (approximately $925 million USD), up from ₹7,149.65 crore in the same quarter last year.
- 04The company's revenue growth in Q4 reflects a significant improvement from ₹8,382.12 crore in the previous fiscal year.
- 05Aurobindo Pharma's performance indicates resilience in the pharmaceutical sector despite rising operational costs.
Advertisement
In-Article Ad
Aurobindo Pharma Ltd, a prominent player in the pharmaceutical industry based in New Delhi, has reported a 2% increase in its consolidated profit after tax (PAT) for the fourth quarter ending March 31, reaching ₹920.84 crore (approximately $111 million USD). This is an improvement from the ₹902.83 crore PAT recorded in the same quarter of the previous fiscal year. The company's total revenue from operations for Q4 FY26 stood at ₹8,853.34 crore (around $1.07 billion USD), marking a significant increase from ₹8,382.12 crore in the corresponding period last year. However, total expenses for the quarter also rose to ₹7,677.34 crore (approximately $925 million USD), compared to ₹7,149.65 crore in Q4 of FY25. For the full fiscal year 2026, Aurobindo Pharma reported a consolidated PAT of ₹3,502.97 crore (about $426 million USD), slightly up from ₹3,483.57 crore in FY25. The total revenue for FY26 was ₹33,653.08 crore (around $4.05 billion USD), reflecting the company's robust growth trajectory amidst increasing operational costs.
Advertisement
In-Article Ad
The financial performance of Aurobindo Pharma reflects the health of the pharmaceutical sector in India, which can influence job stability and investment in the industry.
Advertisement
In-Article Ad
Reader Poll
How do you view Aurobindo Pharma's financial growth?
Connecting to poll...
Read the original article
Visit the source for the complete story.